RAB11A

Across TCGA pan-cancer cohorts, RAB11A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAB11A data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RAB11A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAB11A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, BRCA, and UCEC are the cancer types where RAB11A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.122	0.696	<.001	45	view →
BRCA	OS	Median	II,III,IV	0.579	0.958	<.001	26	view →
UCEC	DFS	Median	All	1.000	0.628	.017	10	view →
COAD	OS	Median	III,IV	0.168	0.691	.041	6	view →
SKCM	DFS	Median	All	0.226	0.737	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAB11A–HNSC (DFS)

Open the HNSC breakdown →